Not a good buy right now for an impatient investor: the chart is weak below the key pivot, hedge funds are aggressively selling, and near-term catalysts skew negative (ETF fee pressure + cost guidance concerns).
Upside exists versus many Street targets (high-$20s to mid-$30s), but the risk/reward today isn’t compelling enough to justify chasing an entry pre-market.
Options activity is elevated: today’s volume is ~5.95x the 30-day average → suggests traders are actively positioning.
IV (30d) ~37.42 vs HV ~37.58 → implied roughly matches realized; pricing isn’t screaming mispriced.
IV percentile ~68.5 (relatively elevated vs its own history) while IV is below the 5D/10D averages → volatility has been coming down, consistent with post-event normalization.
Technical Summary
Sell
5
Buy
9
Positive Catalysts
Wall Street remains constructive on the medium-term story: multiple Buy/Outperform views and price targets commonly above the current price.
Reported business momentum items cited by analysts: net long-term inflows (~$19.1B) and 10 consecutive quarters of positive inflows (per analyst note summary).
Operating leverage / margin expansion theme remains a recurring bullish point in recent research notes.
Revenue: $1.133B, +6.24% YoY → top-line growth is positive.
Profitability: Net income -$1.186B (-666.75% YoY) and EPS -2.63 (-671.74% YoY) → very weak bottom-line trend in the reported quarter (regardless of whether driven by one-offs, the print is directionally negative in this snapshot).
Overall: growth on revenue, but earnings quality/profitability in the latest quarter is a major concern for buying “right now.”
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: price targets were mostly adjusted upward or mixed after Q4, but ratings skew Neutral/Equal Weight at several large firms.
More cautious takes: Goldman, BofA, Morgan Stanley, Barclays largely sit at Neutral/Equal Weight with PTs around $28–$29.5.
Wall Street “pros” case: improving organic growth/inflows + operating leverage and potential margin expansion.
Wall Street “cons” case: expense/cost outlook and fee/distribution pressures; mixed conviction (many neutrals) suggests the Street likes the story but isn’t unanimous on near-term upside.
Wall Street analysts forecast IVZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVZ is 28.68 USD with a low forecast of 25 USD and a high forecast of 33.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast IVZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVZ is 28.68 USD with a low forecast of 25 USD and a high forecast of 33.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
7 Hold
0 Sell
Moderate Buy
Current: 25.770
Low
25
Averages
28.68
High
33.5
Current: 25.770
Low
25
Averages
28.68
High
33.5
Goldman Sachs
Neutral
maintain
AI Analysis
2026-01-28
Reason
Goldman Sachs
Price Target
AI Analysis
2026-01-28
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Invesco to $29.50 from $28.75 and keeps a Neutral rating on the shares.
TD Cowen
Buy
maintain
2026-01-28
Reason
TD Cowen
Price Target
2026-01-28
maintain
Buy
Reason
TD Cowen raised the firm's price target on Invesco to $34.50 from $33.50 and keeps a Buy rating on the shares. The firm updated its model following better than expected Q4 results and Cowen raised its estimates above consensus on its expanding operating leverage.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IVZ
